Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Palandri F, Schaap NPM, Rey J, von Bubnoff N, Reiter A, Hernandez-Boluda JC, Devos T, Nilsson L, Psaila B, McLornan DP, Strouse B, Zhang S, Patel B, Lim J, Patnaik D, Oh ST

Open source

DOI
10.1016/j.clml.2026.02.004
Published
2026 May
Container
Clinical lymphoma, myeloma & leukemia
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clml.2026.02.004,
  title = {Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.},
  author = {Palandri F and Schaap NPM and Rey J and von Bubnoff N and Reiter A and Hernandez-Boluda JC and Devos T and Nilsson L and Psaila B and McLornan DP and Strouse B and Zhang S and Patel B and Lim J and Patnaik D and Oh ST},
  year = {2026},
  journal = {Clinical lymphoma, myeloma \& leukemia},
  doi = {10.1016/j.clml.2026.02.004},
  url = {https://doi.org/10.1016/j.clml.2026.02.004}
}

RIS

TY  - JOUR
TI  - Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.
AU  - Palandri F
AU  - Schaap NPM
AU  - Rey J
AU  - von Bubnoff N
AU  - Reiter A
AU  - Hernandez-Boluda JC
AU  - Devos T
AU  - Nilsson L
AU  - Psaila B
AU  - McLornan DP
AU  - Strouse B
AU  - Zhang S
AU  - Patel B
AU  - Lim J
AU  - Patnaik D
AU  - Oh ST
PY  - 2026
JO  - Clinical lymphoma, myeloma & leukemia
DO  - 10.1016/j.clml.2026.02.004
UR  - https://doi.org/10.1016/j.clml.2026.02.004
ER  - 

APA

F, P., NPM, S., J, R., N, V. B., A, R., JC, H., T, D., L, N., B, P., DP, M., B, S., S, Z., B, P., J, L., D, P., & ST, O. (2026). Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.02.004

Source records